Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8621409 | 0.77 | TSHR (0.43) | TSHR | |
| SCHEMBL4419149 | 0.74 | — | — | |
| SCHEMBL22109759 | 0.72 | TSHR (0.43) | TSHR | |
| SCHEMBL134403 | 0.70 | TSHR (0.41) | TSHR | |
| SCHEMBL8625736 | 0.70 | TSHR (0.41) | TSHR | |
| SCHEMBL10060185 | 0.69 | — | — | |
| SCHEMBL19601236 | 0.68 | TSHR (0.39) | TSHR | |
| SCHEMBL4998283 | 0.68 | TSHR (0.39) | TSHR | |
| SCHEMBL2451380 | 0.67 | TSHR (0.38) | TSHR | |
| SCHEMBL677243 | 0.65 | TSHR (0.36) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110870112-B | Lithium ion secondary battery | 日本电气株式会社 | 2024-09-20 | — | — | CN | disclosed |
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-15 | — | — | US | disclosed |
| US-11817546-B2 | Lithium ion secondary battery | NEC CORPORATION (JP) | 2023-11-14 | — | — | US | disclosed |
| EP-4225749-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | Cullgen (Shanghai), Inc. (CN) | 2023-08-16 | — | — | EP | disclosed |
| CN-116583509-A | Compounds and methods for treating cancer | 上海睿跃生物科技有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-109690861-B | Lithium ion secondary battery | 日本电气株式会社 | 2023-01-06 | — | — | CN | disclosed |
| WO-2022073469-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022073469-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2022-04-14 | — | — | WO | disclosed |
| US-11251424-B2 | Lithium ion secondary battery | NEC CORPORATION (JP) | 2022-02-15 | — | — | US | disclosed |
| US-20210151749-A1 | LITHIUM ION SECONDARY BATTERY | NEC CORPORATION (JP) | 2021-05-20 | — | — | US | disclosed |
| US-20170214087-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND SECONDARY BATTERY | NEC CORPORATION (JP) | 2017-07-27 | — | — | US | disclosed |
| US-20170214087-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND SECONDARY BATTERY | NEC CORPORATION (JP) | 2017-07-27 | — | — | US | disclosed |
| US-9563124-B2 | Photoresist composition and method for producing photoresist pattern | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-02-07 | — | — | US | disclosed |
| US-20140030654-A1 | PHOTORESIST COMPOSITION AND METHOD FOR PRODUCING PHOTORESIST PATTERN | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-01-30 | — | — | US | disclosed |
| JP-2005336246-A | ACID DIANHYDRIDE, ORIENTED FILM AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORP | 2005-12-08 | — | — | JP | disclosed |
| US-4456768-A | Chemical synthesis | THE UNIVERSITY OF CHICAGO (US) | 1984-06-26 | — | — | US | disclosed |
| US-4324730-A | Certain fluorine substituted PGI2 compounds | THE UNIVERSITY OF CHICAGO (US) | 1982-04-13 | — | — | US | disclosed |
| EP-0037422-A4 | FLUORO-SUBSTITUTED PROSTAGLANDINS AND PROSTACYCLINS. | UNIV CHICAGO (US) | 1982-01-26 | — | — | EP | disclosed |
| EP-0037422-A1 | FLUORO-SUBSTITUTED PROSTAGLANDINS AND PROSTACYCLINS | UNIVERSITY OF CHICAGO (US) | 1981-10-14 | — | — | EP | disclosed |
| WO-1981001002-A1 | FLUORO-SUBSTITUTED PROSTAGLANDINS AND PROSTACYCLINS | UNIV CHICAGO (US) | 1981-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GGT1, VHL | TSHR 2695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.